The post-marketing pharmacovigilance and medical information market size has grown rapidly in recent years. It will grow from $6.9 billion in 2025 to $7.71 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to limited post-marketing surveillance infrastructure, reliance on manual ADR reporting, growing regulatory requirements for drug safety, increased number of new drug approvals, lack of integrated hospital data systems.
The post-marketing pharmacovigilance and medical information market size is expected to see rapid growth in the next few years. It will grow to $11.89 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to integration of ai and ml algorithms in signal detection, adoption of longitudinal patient data analysis, expansion of disease registry-linked monitoring, increasing digital app-based reporting, rising investments in real-time pharmacovigilance technologies. Major trends in the forecast period include increasing adoption of electronic health record (ehr) mining, rising use of real-time adverse drug reaction (adr) monitoring systems, growth in risk population-based and therapeutic class-based reporting, expansion of cohort event monitoring for new drug users, integration of digital and mobile platforms for pharmacovigilance reporting.
The climbing rate of adverse drug reactions is set to accelerate the post-marketing pharmacovigilance and medical information market ahead. Adverse drug reactions are noxious or unplanned responses from drugs used at normal doses for prevention, diagnosis, or care. Their frequency grows with an aging populace managing multiple chronic issues via polypharmacy, amplifying risks of interactions and surprises. Post-marketing pharmacovigilance and medical information tackle these by spotting, logging, and disseminating post-launch side effect data to uphold drug safety and utility. For example, in January 2023, Navikenz, a US AI-driven IT services firm, estimated US adverse drug reactions claim 200,000-400,000 lives yearly - outpacing stroke and diabetes combined - with 2.7 million cases sparking over 100,000 hospital stays and 15,000+ deaths. Thus, the surging adverse drug reactions are propelling the post-marketing pharmacovigilance and medical information market.
Leading companies in the post-marketing pharmacovigilance and medical information market are advancing tools like AI-powered pharmacovigilance workflows to sharpen event spotting and deliver instant safety oversight for superior patient results. AI-powered pharmacovigilance workflows harness artificial intelligence for automated safety surveillance, hastening detection and bolstering compliance. For instance, in January 2024, PubHive Ltd., a UK cloud SaaS provider, rolled out centralized Summary of Product Characteristics (SmPC) management for life sciences and research. The system unifies vital safety data in one hub, automates lit scanning and reports, fosters collaboration, and eases rules via AI smarts - empowering teams for proactive, efficient ops that safeguard patients and meet regs.
In October 2023, Ergomed plc, a UK pharma services firm, bought Panacea Pharma Projects Limited for an undisclosed sum. This expands Ergomed's PrimeVigilance unit, amps capabilities, and widens reach to cement leadership in pharmacovigilance. Panacea Pharma Projects Limited is a UK consultancy expert in pharmacovigilance (PV) and medical info, including post-market aid.
Major companies operating in the post-marketing pharmacovigilance and medical information market are Accenture plc, Sanofi S.A., Capgemini SE, Merck & Co. Inc., Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., HCL Technologies Limited, ICON plc, Syneos Health Inc., Genpact Limited, Parexel International Corporation, Avalere Health LLC, Quanticate Limited, Inizio Consulting LLC.
North America was the largest region in the post-marketing pharmacovigilance and medical information market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-marketing pharmacovigilance and medical information market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the post-marketing pharmacovigilance and medical information market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the post-marketing pharmacovigilance and medical information market by increasing costs of imported software solutions, analytical tools, and digital monitoring platforms. Segments like electronic health record (EHR) mining and real-time ADR monitoring systems are most affected, particularly in North America and Europe where imports are significant. This has led to increased operational costs and slower technology adoption. However, tariffs have encouraged local development of pharmacovigilance platforms, innovation in AI-based monitoring tools, and greater domestic investment in medical information services.
The post-marketing pharmacovigilance and medical information market research report is one of a series of new reports that provides post-marketing pharmacovigilance and medical information market statistics, including post-marketing pharmacovigilance and medical information industry global market size, regional shares, competitors with a post-marketing pharmacovigilance and medical information market share, detailed post-marketing pharmacovigilance and medical information market segments, market trends and opportunities, and any further data you may need to thrive in the post-marketing pharmacovigilance and medical information industry. This post-marketing pharmacovigilance and medical information market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Post-marketing pharmacovigilance involves the ongoing monitoring of a drug’s safety after it has been released on the market, aiming to detect, assess, and prevent adverse effects or other drug-related issues. Medical information services provide accurate, scientific, and up-to-date responses to healthcare providers and patients regarding a drug’s use, safety, and efficacy. Together, these processes protect patient health, ensure regulatory compliance, and improve treatment outcomes.
The main types of post-marketing pharmacovigilance and medical information include spontaneous reporting, intensified adverse drug reaction (ADR) reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining. Spontaneous reporting involves healthcare professionals or patients voluntarily identifying and reporting unexpected reactions linked to medication use to authorized organizations. It includes product formats such as books, online media, and journals, and serves a variety of end users, including hospitals, research organizations, and others.
The post-marketing pharmacovigilance and medical information market includes revenues earned by entities by providing services such as adverse event reporting and management, signal detection and risk assessment, drug safety database, medical call center services, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The post-marketing pharmacovigilance and medical information market size is expected to see rapid growth in the next few years. It will grow to $11.89 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to integration of ai and ml algorithms in signal detection, adoption of longitudinal patient data analysis, expansion of disease registry-linked monitoring, increasing digital app-based reporting, rising investments in real-time pharmacovigilance technologies. Major trends in the forecast period include increasing adoption of electronic health record (ehr) mining, rising use of real-time adverse drug reaction (adr) monitoring systems, growth in risk population-based and therapeutic class-based reporting, expansion of cohort event monitoring for new drug users, integration of digital and mobile platforms for pharmacovigilance reporting.
The climbing rate of adverse drug reactions is set to accelerate the post-marketing pharmacovigilance and medical information market ahead. Adverse drug reactions are noxious or unplanned responses from drugs used at normal doses for prevention, diagnosis, or care. Their frequency grows with an aging populace managing multiple chronic issues via polypharmacy, amplifying risks of interactions and surprises. Post-marketing pharmacovigilance and medical information tackle these by spotting, logging, and disseminating post-launch side effect data to uphold drug safety and utility. For example, in January 2023, Navikenz, a US AI-driven IT services firm, estimated US adverse drug reactions claim 200,000-400,000 lives yearly - outpacing stroke and diabetes combined - with 2.7 million cases sparking over 100,000 hospital stays and 15,000+ deaths. Thus, the surging adverse drug reactions are propelling the post-marketing pharmacovigilance and medical information market.
Leading companies in the post-marketing pharmacovigilance and medical information market are advancing tools like AI-powered pharmacovigilance workflows to sharpen event spotting and deliver instant safety oversight for superior patient results. AI-powered pharmacovigilance workflows harness artificial intelligence for automated safety surveillance, hastening detection and bolstering compliance. For instance, in January 2024, PubHive Ltd., a UK cloud SaaS provider, rolled out centralized Summary of Product Characteristics (SmPC) management for life sciences and research. The system unifies vital safety data in one hub, automates lit scanning and reports, fosters collaboration, and eases rules via AI smarts - empowering teams for proactive, efficient ops that safeguard patients and meet regs.
In October 2023, Ergomed plc, a UK pharma services firm, bought Panacea Pharma Projects Limited for an undisclosed sum. This expands Ergomed's PrimeVigilance unit, amps capabilities, and widens reach to cement leadership in pharmacovigilance. Panacea Pharma Projects Limited is a UK consultancy expert in pharmacovigilance (PV) and medical info, including post-market aid.
Major companies operating in the post-marketing pharmacovigilance and medical information market are Accenture plc, Sanofi S.A., Capgemini SE, Merck & Co. Inc., Cognizant Technology Solutions Corporation, IQVIA Holdings Inc., HCL Technologies Limited, ICON plc, Syneos Health Inc., Genpact Limited, Parexel International Corporation, Avalere Health LLC, Quanticate Limited, Inizio Consulting LLC.
North America was the largest region in the post-marketing pharmacovigilance and medical information market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-marketing pharmacovigilance and medical information market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the post-marketing pharmacovigilance and medical information market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the post-marketing pharmacovigilance and medical information market by increasing costs of imported software solutions, analytical tools, and digital monitoring platforms. Segments like electronic health record (EHR) mining and real-time ADR monitoring systems are most affected, particularly in North America and Europe where imports are significant. This has led to increased operational costs and slower technology adoption. However, tariffs have encouraged local development of pharmacovigilance platforms, innovation in AI-based monitoring tools, and greater domestic investment in medical information services.
The post-marketing pharmacovigilance and medical information market research report is one of a series of new reports that provides post-marketing pharmacovigilance and medical information market statistics, including post-marketing pharmacovigilance and medical information industry global market size, regional shares, competitors with a post-marketing pharmacovigilance and medical information market share, detailed post-marketing pharmacovigilance and medical information market segments, market trends and opportunities, and any further data you may need to thrive in the post-marketing pharmacovigilance and medical information industry. This post-marketing pharmacovigilance and medical information market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Post-marketing pharmacovigilance involves the ongoing monitoring of a drug’s safety after it has been released on the market, aiming to detect, assess, and prevent adverse effects or other drug-related issues. Medical information services provide accurate, scientific, and up-to-date responses to healthcare providers and patients regarding a drug’s use, safety, and efficacy. Together, these processes protect patient health, ensure regulatory compliance, and improve treatment outcomes.
The main types of post-marketing pharmacovigilance and medical information include spontaneous reporting, intensified adverse drug reaction (ADR) reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining. Spontaneous reporting involves healthcare professionals or patients voluntarily identifying and reporting unexpected reactions linked to medication use to authorized organizations. It includes product formats such as books, online media, and journals, and serves a variety of end users, including hospitals, research organizations, and others.
The post-marketing pharmacovigilance and medical information market includes revenues earned by entities by providing services such as adverse event reporting and management, signal detection and risk assessment, drug safety database, medical call center services, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Post-Marketing Pharmacovigilance and Medical Information Market Characteristics
3. Post-Marketing Pharmacovigilance and Medical Information Market Supply Chain Analysis
4. Global Post-Marketing Pharmacovigilance and Medical Information Market Trends and Strategies
5. Post-Marketing Pharmacovigilance and Medical Information Market Analysis of End Use Industries
7. Global Post-Marketing Pharmacovigilance and Medical Information Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Post-Marketing Pharmacovigilance and Medical Information Total Addressable Market (TAM) Analysis for the Market
9. Post-Marketing Pharmacovigilance and Medical Information Market Segmentation
10. Post-Marketing Pharmacovigilance and Medical Information Market Regional and Country Analysis
11. Asia-Pacific Post-Marketing Pharmacovigilance and Medical Information Market
12. China Post-Marketing Pharmacovigilance and Medical Information Market
13. India Post-Marketing Pharmacovigilance and Medical Information Market
14. Japan Post-Marketing Pharmacovigilance and Medical Information Market
15. Australia Post-Marketing Pharmacovigilance and Medical Information Market
16. Indonesia Post-Marketing Pharmacovigilance and Medical Information Market
17. South Korea Post-Marketing Pharmacovigilance and Medical Information Market
18. Taiwan Post-Marketing Pharmacovigilance and Medical Information Market
19. South East Asia Post-Marketing Pharmacovigilance and Medical Information Market
20. Western Europe Post-Marketing Pharmacovigilance and Medical Information Market
21. UK Post-Marketing Pharmacovigilance and Medical Information Market
22. Germany Post-Marketing Pharmacovigilance and Medical Information Market
23. France Post-Marketing Pharmacovigilance and Medical Information Market
24. Italy Post-Marketing Pharmacovigilance and Medical Information Market
25. Spain Post-Marketing Pharmacovigilance and Medical Information Market
26. Eastern Europe Post-Marketing Pharmacovigilance and Medical Information Market
27. Russia Post-Marketing Pharmacovigilance and Medical Information Market
28. North America Post-Marketing Pharmacovigilance and Medical Information Market
29. USA Post-Marketing Pharmacovigilance and Medical Information Market
30. Canada Post-Marketing Pharmacovigilance and Medical Information Market
31. South America Post-Marketing Pharmacovigilance and Medical Information Market
32. Brazil Post-Marketing Pharmacovigilance and Medical Information Market
33. Middle East Post-Marketing Pharmacovigilance and Medical Information Market
34. Africa Post-Marketing Pharmacovigilance and Medical Information Market
36. Post-Marketing Pharmacovigilance and Medical Information Market Competitive Landscape and Company Profiles
37. Post-Marketing Pharmacovigilance and Medical Information Market Other Major and Innovative Companies
40. Post-Marketing Pharmacovigilance and Medical Information Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Post-Marketing Pharmacovigilance And Medical Information Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses post-marketing pharmacovigilance and medical information market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for post-marketing pharmacovigilance and medical information? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The post-marketing pharmacovigilance and medical information market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Spontaneous Reporting; Intensified Adverse Drug Reaction (ADR) Reporting; Targeted Spontaneous Reporting; Cohort Event Monitoring; Electronic Health Record (EHR) Mining2) By Publication Type: Books; Online Media; Journals
3) By End User: Hospitals; Research Organizations; Other End-Users
Subsegments:
1) By Spontaneous Reporting: Consumer Reporting; Healthcare Professional Reporting; Regulatory Authority Reporting; Pharmaceutical Company Reporting; Digital App-Based Reporting2) By Intensified Adverse Drug Reaction (ADR) Reporting: Hospital-Based Surveillance; Program-Specific Monitoring; Disease-Specific Monitoring; Product-Specific Monitoring; Real-Time Monitoring Systems
3) By Targeted Spontaneous Reporting: Risk Population-Based Reporting; Therapeutic Class-Based Reporting; Adverse Drug Reaction Focused Reporting; Region-Specific Reporting; Healthcare Setting-Specific Reporting
4) By Cohort Event Monitoring: Prospective Cohort Monitoring; Retrospective Cohort Monitoring; Active Follow-Up Monitoring; New Drug User Monitoring; Disease Registry-Linked Monitoring
5) By Electronic Health Record (EHR) Mining: Natural Language Processing-Based Mining; Artificial Intelligence (AI) And Machine Learning Algorithms; Rule-Based Signal Detection; Longitudinal Patient Data Analysis; Integrated Hospital Data Systems
Companies Mentioned: Accenture plc; Sanofi S.A.; Capgemini SE; Merck & Co. Inc.; Cognizant Technology Solutions Corporation; IQVIA Holdings Inc.; HCL Technologies Limited; ICON plc; Syneos Health Inc.; Genpact Limited; Parexel International Corporation; Avalere Health LLC; Quanticate Limited; Inizio Consulting LLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Post-Marketing Pharmacovigilance and Medical Information market report include:- Accenture plc
- Sanofi S.A.
- Capgemini SE
- Merck & Co. Inc.
- Cognizant Technology Solutions Corporation
- IQVIA Holdings Inc.
- HCL Technologies Limited
- ICON plc
- Syneos Health Inc.
- Genpact Limited
- Parexel International Corporation
- Avalere Health LLC
- Quanticate Limited
- Inizio Consulting LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.71 Billion |
| Forecasted Market Value ( USD | $ 11.89 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
